Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Lee Danner & Bass Inc.

Lee Danner & Bass Inc. decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,631 shares of the medical equipment provider’s stock after selling 120 shares during the quarter. Lee Danner & Bass Inc.’s holdings in Zimmer Biomet were worth $320,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Zimmer Biomet by 1.9% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 18,859 shares of the medical equipment provider’s stock worth $2,295,000 after purchasing an additional 344 shares in the last quarter. Signaturefd LLC lifted its position in Zimmer Biomet by 12.8% during the 4th quarter. Signaturefd LLC now owns 2,146 shares of the medical equipment provider’s stock worth $261,000 after acquiring an additional 243 shares during the period. Lindbrook Capital LLC lifted its position in Zimmer Biomet by 28.1% during the 4th quarter. Lindbrook Capital LLC now owns 1,570 shares of the medical equipment provider’s stock worth $191,000 after acquiring an additional 344 shares during the period. abrdn plc lifted its position in Zimmer Biomet by 54.1% during the 4th quarter. abrdn plc now owns 420,593 shares of the medical equipment provider’s stock worth $51,186,000 after acquiring an additional 147,606 shares during the period. Finally, Naples Money Management LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. Evercore ISI lifted their price target on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Truist Financial lifted their price target on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday, February 9th. Barclays boosted their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Finally, Raymond James boosted their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $139.39.

Insiders Place Their Bets

In other news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $120.78 on Tuesday. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The stock has a 50 day moving average of $126.23 and a two-hundred day moving average of $119.37. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The firm has a market cap of $24.82 billion, a P/E ratio of 24.70, a price-to-earnings-growth ratio of 2.19 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same period in the previous year, the business earned $1.88 EPS. Zimmer Biomet’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.